JP5769733B2 - ピラゾロピリジンキナーゼ阻害剤 - Google Patents

ピラゾロピリジンキナーゼ阻害剤 Download PDF

Info

Publication number: JP5769733B2
Authority: JP; Japan
Prior art keywords: independently; optionally; compound; alkyl; substituted
Prior art date: 2010-01-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2012551251A

Other languages

English (en)

Japanese (ja)

Other versions

JP2013518111A (ja

JP2013518111A5 (2

Inventor

ワーン‐ミゲルジメネズ，

ゴレック，　ジュリアン　エム．シー．

ジュリアンエム．シー．ゴレック，

ルカセッティモ，

ダミアンフレイシー，

ガイブレンチリー，

ディーンボーヤル，

ヘザーツウィン，

スティーブンヤング，

アンドリューダブリュー．ミラー，

クリストファージョンデイビス，

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vertex Pharmaceuticals Inc

Original Assignee

Vertex Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-27

Filing date

2011-01-26

Publication date

2015-08-26

2011-01-26 Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc

2013-05-20 Publication of JP2013518111A publication Critical patent/JP2013518111A/ja

2014-03-13 Publication of JP2013518111A5 publication Critical patent/JP2013518111A5/ja

2015-08-26 Application granted granted Critical

2015-08-26 Publication of JP5769733B2 publication Critical patent/JP5769733B2/ja

Status Active legal-status Critical Current

2031-01-26 Anticipated expiration legal-status Critical

Links

VQTDJPJNXONHNE-UHFFFAOYSA-N CC(C)C(C)(C(C1)NCCN1c(c(Cl)c1[Si](C)(C)C(C)(C)C)nc(-c2n[nH]c3ncccc23)c1F)OC(C)S(C)C Chemical compound CC(C)C(C)(C(C1)NCCN1c(c(Cl)c1[Si](C)(C)C(C)(C)C)nc(-c2n[nH]c3ncccc23)c1F)OC(C)S(C)C VQTDJPJNXONHNE-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

JP2012551251A 2010-01-27 2011-01-26 ピラゾロピリジンキナーゼ阻害剤 Active JP5769733B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US29864910P	2010-01-27	2010-01-27
US61/298,649		2010-01-27
US41042610P	2010-11-05	2010-11-05
US61/410,426		2010-11-05
PCT/US2011/022522 WO2011094273A1 (en)	2010-01-27	2011-01-26	Pyrazolopyridine kinase inhibitors

Publications (3)

Publication Number	Publication Date
JP2013518111A JP2013518111A (ja)	2013-05-20
JP2013518111A5 JP2013518111A5 (2)	2014-03-13
JP5769733B2 true JP5769733B2 (ja)	2015-08-26

Family

ID=44088992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2012551251A Active JP5769733B2 (ja)	2010-01-27	2011-01-26	ピラゾロピリジンキナーゼ阻害剤

Country Status (9)

Country	Link
US (1)	US9067932B2 (2)
EP (1)	EP2528917B1 (2)
JP (1)	JP5769733B2 (2)
CN (1)	CN102858769A (2)
AR (1)	AR080856A1 (2)
AU (1)	AU2011209726A1 (2)
CA (1)	CA2787315A1 (2)
MX (1)	MX2012008644A (2)
WO (1)	WO2011094273A1 (2)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8569337B2 (en)	2008-07-23	2013-10-29	Vertex Pharmaceuticals Incorporated	Tri-cyclic pyrazolopyridine kinase inhibitors
CA2732765A1 (en)	2008-08-06	2010-02-11	Vertex Pharmaceuticals Incorporated	Aminopyridine kinase inhibitors
MX2012008642A (es) *	2010-01-27	2012-11-23	Vertex Pharma	Inhibidores de cinasas de pirazolopiridinas.
EP2582702A1 (en) *	2010-01-27	2013-04-24	Vertex Pharmaceuticals Incorporated	Pyrazolopyrimidine kinase inhibitors
ES2851724T3 (es)	2013-09-18	2021-09-08	Epiaxis Therapeutics Pty Ltd	Modulación de células madre
CA2958704A1 (en) *	2014-08-25	2016-03-03	University Of Canberra	Compositions for modulating cancer stem cells and uses therefor
WO2019090390A1 (en) *	2017-11-08	2019-05-16	University Of Canberra	Immunogenic compositions and uses therefor
CN118923682B (zh) *	2024-07-22	2025-09-05	中国农业大学	一种化合物作为病原真菌Pmk1的抑制剂的应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3853898A (en)	1971-07-20	1974-12-10	Sandoz Ag	3-(2-substituted amino) pyridyl-phenyl ketone imines
US4988705A (en)	1985-06-13	1991-01-29	Schering Corporation	Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
FR2601015B1 (fr)	1986-07-04	1988-08-05	Rhone Poulenc Sante	Nouveaux derives du 1h,3h-pyrrolo (1,2-c) thiazole, leur preparation et les compositions pharmaceutiques qui les contiennent
DE3827253A1 (de)	1987-08-20	1989-03-02	Sandoz Ag	Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
CA1339423C (en)	1988-09-14	1997-09-02	Yuji Ono	Pyridine compounds and pharmaceutical use thereof
US5100768A (en)	1989-05-09	1992-03-31	Kabushiki Kaisha Toshiba	Photosensitive composition
JPH03206450A (ja)	1990-01-09	1991-09-09	Fuji Photo Film Co Ltd	新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料及びその処理方法
US5308854A (en)	1990-06-18	1994-05-03	Merck & Co., Inc.	Inhibitors of HIV reverse transcriptase
JPH05331163A (ja)	1991-03-26	1993-12-14	Kumiai Chem Ind Co Ltd	ピリジン誘導体及び除草剤
UA44220C2 (uk)	1991-11-07	2002-02-15	Агрево Юк Лімітед	Сульфонаміди,що мають гербіцидну активність,спосіб їх одержання, гербіцидна композиція та спосіб боротьби з бур'янами
US5476750A (en)	1992-12-29	1995-12-19	Hoechst Celanese Corporation	Metal ion reduction in the raw materials and using a Lewis base to control molecular weight of novolak resin to be used in positive photoresists
DK0700384T3 (da)	1993-05-28	1997-12-08	Pfizer	fremgangsmåde til fremstilling og opløsning af 2-phenyl-3-aminopiperidin
CA2133355A1 (en)	1993-10-04	1995-04-05	Itaru Nitta	Method for producing polypeptide
WO1995032963A1 (en)	1994-06-01	1995-12-07	Yoshitomi Pharmaceutical Industries, Ltd.	Thienylazole compound and thienotriazolodiazepine compound
WO1996006843A1 (en)	1994-08-29	1996-03-07	Yamanouchi Pharmaceutical Co., Ltd.	Novel naphthyridine derivative and medicinal composition thereof
US5646330A (en)	1995-02-17	1997-07-08	Ciba-Geigy Corporation	Production of enantiomerically enriched ortho-substituted α,α-diaromatic methanols
US6194581B1 (en)	1995-04-07	2001-02-27	Merck & Co., Inc.	Substituted pyridines useful as modulators of acetylcholine receptors
NZ322197A (en)	1995-11-21	1999-02-25	Yamanouchi Pharma Co Ltd	Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
CN1252718A (zh)	1997-04-18	2000-05-10	橘生药品工业株式会社	预防或治疗与视网膜色素上皮细胞过度增殖相关的疾病的药剂
AU8033598A (en)	1997-06-18	1999-01-04	Nissan Chemical Industries Ltd.	Pyridine compounds and herbicides
US6452008B2 (en)	1998-02-25	2002-09-17	Sumitomo Pharmaceuticals Company, Limited	Pyridone derivatives and process for preparing the same
US6225329B1 (en)	1998-03-12	2001-05-01	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (PTPases)
GB9908410D0 (en)	1999-04-13	1999-06-09	Pfizer Ltd	Pyridines
US6844367B1 (en)	1999-09-17	2005-01-18	Millennium Pharmaceuticals, Inc.	Benzamides and related inhibitors of factor Xa
WO2001083492A1 (en)	2000-05-02	2001-11-08	Newbiotics, Inc.	Improved beta-lactam antibiotics
AR029289A1 (es)	2000-07-05	2003-06-18	Ishihara Sangyo Kaisha	Derivado de benzoilpiridina o su sal, fungicida que lo contiene como un ingrediente activo, su proceso de produccion e intermediario para producirlo
DE10035908A1 (de)	2000-07-21	2002-03-07	Asta Medica Ag	Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
CN1478077A (zh)	2000-10-05	2004-02-25	��ҩƷ��ҵ��ʽ��	作为apo b分泌抑制剂的苯甲酰胺化合物
ES2200617B1 (es)	2001-01-19	2005-05-01	Almirall Prodesfarma, S.A.	Derivados de urea como antagonistas de integrinas alfa 4.
GB2373245A (en)	2001-03-12	2002-09-18	Bayer Ag	Pyridinyl pyrazoles and their use for the treatment of COPD
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
HUP0402106A3 (en)	2001-11-01	2009-07-28	Janssen Pharmaceutica Nv	Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
NZ566263A (en)	2002-05-24	2009-09-25	Millennium Pharm Inc	CCR9 inhibitors and methods of use thereof
EP1545515A1 (en)	2002-08-12	2005-06-29	Sugen, Inc.	3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
US7279576B2 (en)	2002-12-31	2007-10-09	Deciphera Pharmaceuticals, Llc	Anti-cancer medicaments
US7202257B2 (en)	2003-12-24	2007-04-10	Deciphera Pharmaceuticals, Llc	Anti-inflammatory medicaments
HRP20050690A2 (en)	2003-02-07	2006-08-31	Janssen Pharmaceutica N.V.	Hiv inhibiting 1,2,4-triazines
DE602004013427T2 (de)	2003-02-28	2009-06-04	Schering Corp.	Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen
US20050203067A1 (en)	2003-05-12	2005-09-15	Hresko Michelle C.	Pesticidal compositions and methods
WO2005000813A1 (en)	2003-05-30	2005-01-06	Imclone Systems Incorporated	Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
EP1660087A2 (en)	2003-07-22	2006-05-31	Janssen Pharmaceutica N.V.	Quinolinone derivatives as inhibitors of c-fms kinase
CN100475815C (zh)	2003-09-25	2009-04-08	詹森药业有限公司	抑制hiv复制的嘌呤衍生物
WO2005035507A2 (en)	2003-10-10	2005-04-21	Bayer Pharmaceuticals Corporation	4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
JP4805166B2 (ja)	2003-12-22	2011-11-02	バジリアファルマスーチカアーゲー	アロイルフランおよびアロイルチオフェン
UA87494C2 (en) *	2004-03-30	2009-07-27	Вертекс Фармасьютикалс Инкорпорейтед	Azaindoles useful as inhibitors of jak and other protein kinases
ES2364340T3 (es) *	2004-03-30	2011-08-31	Vertex Pharmaceuticals Incorporated	Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
AR049333A1 (es)	2004-04-02	2006-07-19	Vertex Pharma	Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
WO2005111001A1 (en)	2004-05-19	2005-11-24	Astrazeneca Ab	Novel fused heterocycles and uses thereof
WO2006015123A1 (en)	2004-07-27	2006-02-09	Sgx Pharmaceuticals, Inc.	Pyrrolo-pyridine kinase modulators
US7709645B2 (en)	2004-07-27	2010-05-04	Sgx Pharmaceuticals, Inc.	Pyrrolo-pyridine kinase modulators
US7361764B2 (en)	2004-07-27	2008-04-22	Sgx Pharmaceuticals, Inc.	Pyrrolo-pyridine kinase modulators
CA2573573A1 (en) *	2004-07-27	2006-02-09	Sgx Pharmaceuticals, Inc.	Fused ring heterocycle kinase modulators
US20090227799A1 (en)	2004-08-09	2009-09-10	Kazutaka Nakamoto	Novel Antimalarial Agent Containing Heterocyclic Compound
ATE554087T1 (de)	2004-10-29	2012-05-15	Abbott Lab	Neue kinaseinhibitoren
WO2006058120A1 (en) *	2004-11-22	2006-06-01	Vertex Pharmaceuticals Incorporated	Bicyclic inhibitors or rho kinase
WO2006074984A1 (en)	2005-01-14	2006-07-20	Janssen Pharmaceutica N.V.	Pyrazolopyrimidines as cell cycle kinase inhibitors
US7622583B2 (en)	2005-01-14	2009-11-24	Chemocentryx, Inc.	Heteroaryl sulfonamides and CCR2
WO2006099972A1 (en)	2005-03-23	2006-09-28	F. Hoffmann-La Roche Ag	Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists
AU2006232517A1 (en)	2005-04-04	2006-10-12	Eisai R&D Management Co., Ltd.	Dihydropyridine compounds and compositions for headaches
BRPI0607913A2 (pt)	2005-04-08	2010-03-23	Eisai R&D Man Co Ltd	agente terapÊutico para discinesia
RU2387653C2 (ru)	2005-05-16	2010-04-27	Айрм Ллк	Соединения и композиции в качестве ингибиторов протеинкиназ
US7547782B2 (en)	2005-09-30	2009-06-16	Bristol-Myers Squibb Company	Met kinase inhibitors
ZA200802685B (en) *	2005-09-30	2009-10-28	Vertex Pharma	Deazapurines useful as inhibitors of janus kinases
DE102006029447A1 (de) *	2006-06-21	2007-12-27	Bayer Schering Pharma Ag	Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
US8519135B2 (en)	2006-07-14	2013-08-27	Chemocentryx, Inc.	Heteroaryl sulfonamides and CCR2/CCR9
AU2008210455A1 (en)	2007-01-31	2008-08-07	Vertex Pharmaceuticals Incorporated	2-aminopyridine derivatives useful as kinase inhibitors
AR066477A1 (es) *	2007-05-09	2009-08-19	Novartis Ag	Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
JP4946728B2 (ja)	2007-08-23	2012-06-06	三菱電機株式会社	電力増幅器
TW200924762A (en) *	2007-11-02	2009-06-16	Vertex Pharma	Kinase inhibitors
AU2009274023A1 (en) *	2008-07-23	2010-01-28	Vertex Pharmaceuticals Incorporated	Tri-cyclic pyrazolopyridine kinase inhibitors
US8569337B2 (en) *	2008-07-23	2013-10-29	Vertex Pharmaceuticals Incorporated	Tri-cyclic pyrazolopyridine kinase inhibitors
EP2321318A1 (en) *	2008-07-23	2011-05-18	Vertex Pharmaceuticals Incorporated	Pyrazolopyridine kinase inhibitors
ES2402087T3 (es) *	2008-07-23	2013-04-26	Vertex Pharmaceuticals Incorporated	Inhibidores de la pirazolopiridina quinasa
MX2011000843A (es) *	2008-07-23	2011-04-11	Vertex Pharma	Inhibidores de pirazolopiridin cinasa triciclicos.
MX2012008642A (es) *	2010-01-27	2012-11-23	Vertex Pharma	Inhibidores de cinasas de pirazolopiridinas.

2011
- 2011-01-26 JP JP2012551251A patent/JP5769733B2/ja active Active
- 2011-01-26 CA CA2787315A patent/CA2787315A1/en not_active Abandoned
- 2011-01-26 CN CN2011800130461A patent/CN102858769A/zh active Pending
- 2011-01-26 EP EP11703958.6A patent/EP2528917B1/en active Active
- 2011-01-26 US US13/014,505 patent/US9067932B2/en active Active
- 2011-01-26 MX MX2012008644A patent/MX2012008644A/es active IP Right Grant
- 2011-01-26 AU AU2011209726A patent/AU2011209726A1/en not_active Abandoned
- 2011-01-26 WO PCT/US2011/022522 patent/WO2011094273A1/en not_active Ceased
- 2011-01-27 AR ARP110100282A patent/AR080856A1/es unknown

Also Published As

Publication number	Publication date
EP2528917A1 (en)	2012-12-05
JP2013518111A (ja)	2013-05-20
WO2011094273A1 (en)	2011-08-04
CN102858769A (zh)	2013-01-02
US9067932B2 (en)	2015-06-30
US20120071494A1 (en)	2012-03-22
AR080856A1 (es)	2012-05-16
MX2012008644A (es)	2012-11-23
EP2528917B1 (en)	2016-10-19
CA2787315A1 (en)	2011-08-04
AU2011209726A1 (en)	2012-08-09

Legal Events

Date	Code	Title	Description
2014-01-24	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140123
2014-01-24	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140123
2014-12-01	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20141128
2014-12-05	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141204
2015-03-02	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150302
2015-06-01	TRDD	Decision of grant or rejection written
2015-06-05	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150604
2015-07-02	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150623
2015-07-03	R150	Certificate of patent or registration of utility model	Ref document number: 5769733 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2018-07-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-07-02	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2020-06-26	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-06-25	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-06-24	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-06-23	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-07-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-07-02	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP5931976B2 (ja)	2016-06-08	三環式ピラゾロピリジンキナーゼ阻害剤
JP5631310B2 (ja)	2014-11-26	三環式ピラゾロピリジンキナーゼ阻害剤
JP5542287B2 (ja)	2014-07-09	ピラゾロピリジンキナーゼ阻害剤
JP5627675B2 (ja)	2014-11-19	ピラゾロピリジン
JP2011529062A (ja)	2011-12-01	ピラゾロピリジンキナーゼ阻害剤
JP5769733B2 (ja)	2015-08-26	ピラゾロピリジンキナーゼ阻害剤
JP2013518112A (ja)	2013-05-20	ピラゾロピリジンキナーゼ阻害剤
JP2011530527A (ja)	2011-12-22	アミノピリジンキナーゼ阻害剤
US8895740B2 (en)	2014-11-25	Pyrazolopyrazine kinase inhibitors
JP2013518114A (ja)	2013-05-20	ピラゾロピリミジンキナーゼ阻害剤